Chemical industry in Austria

Revamps of 550 and 1,900 MTPD ammonia units will modernize reformers, add a new synthesis converter, cut natural gas use and lower CO₂ emissions.

EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.

VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.

VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.

Rapid, significant relief in skin clearance, itch, pain and patient satisfaction versus placebo; consistent safety and fewer patients required rescue medication.

€1bn Europe-wide auction for industrial process-heat decarbonisation; bidding opens early Dec 2026. Supports electrification, renewable heat and SMRs with a fixed premium per tCO2.

CHMP found methodological limits in existing efficacy studies and asked companies to run new post‑authorisation trials; medicines remain available in Austria and Italy and no new safety concerns were found.

CHMP limits ipidacrine to specific neuropathies, Alzheimer’s, intestinal atony and certain stroke/TBI recovery uses; removes several neuritis and demyelinating indications; cautions >80 mg/day.

SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.